Outcomes of Pregnancy in COVID-19-Positive Mothers in a Tertiary Centre.
COVID-19
infection
maternal
perinatal
pregnancy
vaccination
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
30 Jun 2023
30 Jun 2023
Historique:
received:
13
06
2023
revised:
26
06
2023
accepted:
29
06
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
COVID-19 is an emerging global pandemic with potential adverse effects during pregnancy. This study aimed to determine the adverse maternal and foetal outcomes due to COVID-19 infection. We also compared maternal and neonatal outcomes with regard to the timing of diagnosis (first and second trimester vs. third and fourth trimester); early COVID-19 (stage I and II) vs. severe-stage COVID-19 (III, IV, and V); and lastly, women who were partially vaccinated vs. unvaccinated. This was a retrospective study conducted in HCTM from January 2021 to January 2022. All pregnant women admitted for COVID-19 infections were recruited. The patients' records were traced. Adverse maternal and neonatal outcomes were documented and analysed. There were 172 pregnant women recruited into this study. We excluded twenty-four patients with incomplete data and nine women who delivered elsewhere. The final 139 patients were available for data analysis. The majority of women were in their third trimester of pregnancy (87.8%); however, only 5.0% and 7.2% were in the first and second trimesters, respectively. The study population had a median BMI of 29.1 kg/m Adverse pregnancy outcomes such as ICU admission or patient death could occur; however, the clinical course of COVID-19 in most women was not severe and the infection did not significantly influence the pregnancy. The risk of preterm birth before 34 weeks was higher in a more severe-stage disease and unvaccinated mother. The findings from this study can guide and enhance antenatal counselling of women with COVID-19 infection, although they should be interpreted with caution in view of the very small number of included cases of patients in the first and second trimesters.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 is an emerging global pandemic with potential adverse effects during pregnancy. This study aimed to determine the adverse maternal and foetal outcomes due to COVID-19 infection. We also compared maternal and neonatal outcomes with regard to the timing of diagnosis (first and second trimester vs. third and fourth trimester); early COVID-19 (stage I and II) vs. severe-stage COVID-19 (III, IV, and V); and lastly, women who were partially vaccinated vs. unvaccinated.
METHODS
METHODS
This was a retrospective study conducted in HCTM from January 2021 to January 2022. All pregnant women admitted for COVID-19 infections were recruited. The patients' records were traced. Adverse maternal and neonatal outcomes were documented and analysed.
RESULTS
RESULTS
There were 172 pregnant women recruited into this study. We excluded twenty-four patients with incomplete data and nine women who delivered elsewhere. The final 139 patients were available for data analysis. The majority of women were in their third trimester of pregnancy (87.8%); however, only 5.0% and 7.2% were in the first and second trimesters, respectively. The study population had a median BMI of 29.1 kg/m
CONCLUSIONS
CONCLUSIONS
Adverse pregnancy outcomes such as ICU admission or patient death could occur; however, the clinical course of COVID-19 in most women was not severe and the infection did not significantly influence the pregnancy. The risk of preterm birth before 34 weeks was higher in a more severe-stage disease and unvaccinated mother. The findings from this study can guide and enhance antenatal counselling of women with COVID-19 infection, although they should be interpreted with caution in view of the very small number of included cases of patients in the first and second trimesters.
Identifiants
pubmed: 37511865
pii: life13071491
doi: 10.3390/life13071491
pmc: PMC10381457
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Ultrasound Obstet Gynecol. 2020 Jul;56(1):15-27
pubmed: 32430957
Int J Environ Res Public Health. 2021 May 27;18(11):
pubmed: 34072017
Clin Microbiol Infect. 2021 Jan;27(1):36-46
pubmed: 33148440
Front Public Health. 2021 May 07;9:560592
pubmed: 34026696
Med J Malaysia. 2021 Jan;76(1):1-4
pubmed: 33510100
PLoS One. 2021 Apr 22;16(4):e0250196
pubmed: 33886645
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Obstet Gynaecol. 2023 Dec;43(1):2162867
pubmed: 36651606
PLoS One. 2022 Jul 8;17(7):e0270868
pubmed: 35802652
J Infect Public Health. 2020 Dec;13(12):1823-1829
pubmed: 32896496
PLoS Negl Trop Dis. 2022 Nov 8;16(11):e0010887
pubmed: 36346816
Arch Gynecol Obstet. 2021 Jul;304(1):5-38
pubmed: 33797605
Int J Infect Dis. 2020 Aug;97:108-116
pubmed: 32497808
PLoS One. 2021 Mar 23;16(3):e0249090
pubmed: 33755688
Front Public Health. 2020 Nov 23;8:558144
pubmed: 33330308
Clin Obstet Gynecol. 2022 Mar 1;65(1):110-122
pubmed: 35045034
J Perinat Med. 2023 Feb 17;:
pubmed: 36800343
Vaccine. 2021 Oct 1;39(41):6037-6040
pubmed: 34531079
Int J Gynaecol Obstet. 2022 Mar;156(3):394-405
pubmed: 34762735
Am J Obstet Gynecol MFM. 2020 May;2(2):100107
pubmed: 32292902
Ann Acad Med Singap. 2020 Nov;49(11):857-869
pubmed: 33381779
Front Public Health. 2023 Feb 22;11:1092724
pubmed: 36908400
PLoS One. 2020 Jun 4;15(6):e0234187
pubmed: 32497090
Acta Obstet Gynecol Scand. 2020 Jul;99(7):823-829
pubmed: 32259279
PLoS One. 2021 Mar 25;16(3):e0248916
pubmed: 33765039